Gene Mutations in Non-Small Cell Lung Cancer Cells

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-11-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To compare the frequency of individual genetic abnormality between tumor cells and blood specimens.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genotyping of Non-small Cell Lung Cancer

NCT02002117

Non-small Cell Lung Cancer Gene Abnormality

UNKNOWN

Next-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess Treatment

NCT03244904

SCLC

UNKNOWN

Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC

NCT02422628

Lung Cancer

UNKNOWN

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China

NCT03059641

Lung Neoplasms Lung Cancer, Nonsmall Cell Adenocarcinoma of Lung +1 more

COMPLETED

The Correlation Between Lung Cancer Susceptibility, Drug Response and Genetic Polymorphism

NCT01280448

Lung Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Samples will be collected before the systemic therapy. After initiation of therapy, samples will be collected at end of the 1st month, at the end of the 2nd month at the end of 3rd months and once every three months thereafter concurrently with the tumor assessment such as time of performing CT scans. In selected consented patients, peripheral blood samples will be collected every week for the first month.

Disease status will be assessed every 2\~3 months and at the end of treatment according to RECIST criteria. If progression is not observed at the end of therapy, patients will be assessed every 3 months until progression or further anti-cancer therapy. Progression-free survival, overall survival and response rate will be reported.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small-Cell Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pathologic or cytological confirmation of NSCLC.
* Patients must understand and provide written informed consent prior to initiation of any study-specific procedures.
* Have a life expectancy 3 months.
* Have malignant pleural/pericardial effusion or metastatic non-small cell lung cancer.
* Have measurable or evaluable disease.
* ≥20 years.
* Candidate for systemic treatment such as EGFR-TKI or chemotherapy.

Exclusion Criteria

* Prior history of another malignancy (other than cured basal cell carcinoma of the skin or cured in-situ carcinoma of the cervix) within 5 years of study entry.

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No